Evidence map›Paper›PMID 35895368›Full record

ArticleThe American journal of tropical medicine and hygiene2022

Characterization of Recalcitrant Dermatophytosis in a Multicenter Study in Sri Lanka.

Nayani P Madarasingha, Surammika Eriyagama, Primali I Jayasekera, Shreenika de Silva Weliange, Saman Gunasekera, D M Munasingha, Premini Rajendran, S M B Ekanayaka, Janani Liyanange, N Thamilvannan and 3 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Global Emergence ofInfection and drug resistance · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Nayani P MadarasinghaNational, Institute of Infectious Diseases, Colombo, Sri Lanka.
Surammika EriyagamaBase Hospital, Gampola, Sri Lanka.
Primali I JayasekeraMedical Research Institute, Colombo, Sri Lanka.
Shreenika de Silva WeliangeFaculty of Medicine, Colombo, Sri Lanka.
Saman GunasekeraColombo South Teaching Hospital, Colombo, Sri Lanka.
D M MunasinghaTeaching Hospital, Kandy, Sri Lanka.
Premini RajendranBase Hospital, Chilaw, Sri Lanka.
S M B EkanayakaGeneral Hospital, Kegalle, Sri Lanka.
Janani LiyanangeBase Hospital, Mahiyanganaya, Sri Lanka.
N ThamilvannanTeaching Hospital, Batticaolo, Sri Lanka.
Buthsiri SumanasenaTeaching Hospital, Anuradhapura, Sri Lanka.
Felicia SrisaravanabavanathanTeaching Hospital, Jaffna, Sri Lanka.
Binari WijenayakeTeaching Hospital Karapitiya, Galle, Sri Lanka.
Teaching Hospital Kandy · LKNational Hospital of Sri Lanka · LKColombo North Teaching Hospital · LKJaffna Teaching Hospital · LKMedical Research Institute · LKTeaching Hospital Batticaloa · LKUniversity of Colombo · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A changing clinical scenario of dermatophytosis has been observed in Sri Lanka during the past few years. In keeping with the trend described in India, an increase in the number of chronic, relapsing, and recalcitrant infections has been noted. The objective of our study was to assess the therapeutic response of dermatophytosis to standard antifungal treatment in Sri Lanka and to identify possible contributory factors in cases showing inadequate therapeutic response. A descriptive, observational, cross-sectional study was carried out in nine hospitals, representing each province. Over 6 months, patients with dermatophytosis on glabrous skin were included. All subjects underwent skin scrapings for mycological studies and were treated with a standard course of antifungals for a specific period. In those patients who achieved complete clearance, recurrences were noted. The study included 796 patients, of whom 191 (24%) had symptoms for more than 3 months at presentation. A total of 519 patients (65.2%) had multiple-site involvement, and 503 (63.2%) had evidence of prior use of topical steroids. Skin scrapings were positive for fungal elements in the direct smears of 659 patients (82.8%), and the predominant dermatophyte isolated was Trichophyton mentagrophytes (65.6%). Partial responders after 10 weeks of treatment and recurrences after complete clearance were significantly greater in the group that used topical steroids before presentation (P < 0.001). This study highlights the magnitude of the threat of an inadequate therapeutic response in dermatophytosis in Sri Lanka, and identifies steroid misuse, and the shift of the predominant fungal species to T. mentagrophytes as possible causative factors.

Indexed as

TineaAntifungal AgentsCross-Sectional StudiesHumansRecurrenceSri LankaTrichophytonAntifungal Agents

Identifiers

PMID35895368
PMCPMC9294678
OpenAlexW4282832170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.